(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.66%) $83.30
(-1.16%) $1.619
(-0.03%) $2 346.50
(-0.11%) $27.51
(0.13%) $923.30
(-0.08%) $0.934
(-0.01%) $11.02
(-0.11%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...
Stats | |
---|---|
Šios dienos apimtis | 1.91M |
Vidutinė apimtis | 954 093 |
Rinkos kapitalizacija | 6.57B |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -66.29 |
ATR14 | $1.830 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 4 695 639 |
Tūris Koreliacija
Reata Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
CREX | 0.957 |
MYRG | 0.875 |
ALLR | 0.869 |
MSSA | 0.849 |
SGEN | 0.847 |
NETE | 0.835 |
PLYA | 0.832 |
MHUA | 0.831 |
USAP | 0.83 |
SGTX | 0.825 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RMGBU | -0.875 |
ENVI | -0.851 |
EJFA | -0.838 |
ONEM | -0.837 |
ESSA | -0.837 |
SVOK | -0.824 |
SAII | -0.819 |
FNCB | -0.818 |
BSBK | -0.816 |
PAIC | -0.814 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Reata Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos
Reata Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $2.22M |
Bruto pelnas: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2022 |
Pajamos: | $2.22M |
Bruto pelnas: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2021 |
Pajamos: | $11.49M |
Bruto pelnas: | $11.49M (100.00 %) |
EPS: | $-8.19 |
FY | 2020 |
Pajamos: | $9.02M |
Bruto pelnas: | $9.02M (100.00 %) |
EPS: | $-7.35 |
Financial Reports:
No articles found.
Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.